Barely Significant
← all excerpts

Atezolizumab does not improve progression-free survival in patients with recurrent platinum-sensitive ovarian cancer.

Gynecol Pelvic Med · 2024 · PMC13214594 · PMID 42211977

Europe PMCDOI
1
hedged sentence
0.0410
closest p · 0.8× alpha
0.0410
boldest claim

The sentences

marginally significantP=0.041actually significant
Yet, there was a marginally significant improvement in PFS with atezolizumab compared with placebo in the ITT population [hazard ratio (HR), 0.83; 95% confidence interval (CI): 0.69 to 0.99; P=0.041; median PFS 13.5 vs. 11.3 months, respectively].

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.